=============================================================== == == == -- ALS INTEREST GROUP -- == == ALS Digest (#26, 28 FEB 1993) == == == == To subscribe, to unsubscribe, to request back issues, == == to contribute notes, etc. please send e-mail to: == == bro@huey.met.fsu.edu (Bob Broedel) == == == == In the very near future all interested people will be == == able to "broadcast" messages to ALS Digest subscribers == == by sending to: als@huey.met.fsu.edu == == == =============================================================== (1) ===== Building the ALS e-mail network ========== ----- Date : Wed, 17 Feb 1993 14:14:32 EST From : springerj@hal.hahnemann.edu To : broedel@geomag.gly.fsu.edu Subject: ALS network I would be very interested in the proposed network. My research involves the study of neurotrophic factors on the survival and function of motoneurons in ALS spinal cord. We have a strong patient population at Hahnemann and we work very close with the ALS clinic. Please keep me informed of the network. best regards, Joe E. Springer, Ph.D., Associate Professor of Neurology ----- Date : 21 Feb 1993 18:39:52 -0700 (MST) From : WHARRISO@CCIT.ARIZONA.EDU Subject: ALS To : broedel@geomag.gly.fsu.edu My name is Lliam Harrison. I am a Ph.D. candidate in medical anthropology at the University of Arizona in Tucson. My dissertation research is going in the direction of an anthropological study of ALS in Guam, which has had one the highest rates of the disease in the world. I would be interested in sharing information with you and any one else interested in the problem and I would also appreciate any insights anyone might have for me. I hope this message gets through to you and that you have heard from others. ALS is quite an enigma, and I hope that I may be able to help shed some light on it through anthropology. Lliam Harrison ----- Date : Tue, 23 Feb 1993 18:33:34 -0500 (EST) From : Ron Moss Subject: group work query To : broedel@geomag.gly.fsu.edu We saw your ALS group mentioned in a newsletter. We are therapists brand new to this concept/system. Just wanted to reach out/get involved. ---------------------- ronmoss@panix.com ---------------------- Thanks, Ron Moss ----- Date : 26 Feb 93 12:42:04 EST From : AFC04%ALBNYDH2.bitnet@UACSC2.ALBANY.EDU To : Bob Broedel Subject: Subscribe ALS Digest ++++++++++++++++++++++++++++++++++++++++++++++++++++++ SUBSCRIBE ALS-DIGEST Alvaro Carrascal (AFC04@ALBNYDH2) ++++++++++++++++++++++++++++++++++++++++++++++++++++++ Alvaro Carrascal, MD +++++++++++++ Clinical Education Unit, AIDS Institute +++++++++++++ NY State DOH +++++++++++++ ++++++++++++++++++++++++++++++++++++++++++++++++++++++ ----- Sender : wl@carson.u.washington.edu Date : Tue, 23 Feb 1993 18:03:37 -0800 (PST) From : Will Longstreth Subject: ALS To : broedel@geomag.gly.fsu.edu I received your note about ALS and would be interested in participating. I am a neurologist with some training in epidemiology. Along with colleagues in the Departments of Epidemiology, Environmental Health and Biostatistics at the University of Washington, we are currently conducting a population-based case-control study of ALS in King, Pierce and Snohomish counties of western Washington state. Our goal is to try to identify some clues as to the cause of sporadic ALS. We hope that such knowledge will open the possibility of preventing the disease. Let me know if I can help with your project. Good luck. Sincerely, Will Longstreth. (2) ===== From Russia ========== Date : Wed, 24 Feb 93 17:26:42 +0300 To : bro@huey.met.fsu.edu From : icla@immoscow.gtc.de (ICLA mailbox) Subject: REP.ON: TO: ERIK MINSKER (2) Dear Bob! Thank you very much for your answer. I be very grateful if you add my adress to your e-mail list for ALS DIGEST, because your message will be paid by my e-mail sponsors. Thank you very much too for your NOTE to Readers with the idea about sending to my Fund extra copies of books, magasines, articles etc. Now I should like to obtain a copy of "HEALTHY PEOPLE 2000"/Full report:Stock No 017-001-00474-0 or Summary Report:Stock No017-001-00473-1/ though the superintendent of Documents to be able to creat the application for the research project grant /R-01/. To apply for R-01 grant application form PHS 398 /rev.9/91/ is to be used. However, it is trouble for me to obtain these forms for the appliication. Would you be so kind to help me to obtain these application form or to message the address were I can obtain these forms? Sincerely yours, Erik Minsker, Moskow, Russia (3) ===== Spinal cord banks? ========== Date : 24 Feb 93 10:19:26 EST From : Michele Lee To : broedel@geomag.gly.fsu.edu Subject: RE: als 11 Hi! My friend made this inquiry and I don't know whether you've heard anything about this. She works for a pharmaceutical company in the Bay Area which is working on neurological diseases. Personally, I haven't heard about any spinal cord banks, but maybe you have. If you could reply to her, I'd appreciate it. Thanks, Michele *** Forwarding note from SMTP --TJUVM 02/23/93 20:50 *** ================================================================== Date : 23 Feb 93 17:44:06 PST From : "Karen Chen" Subject: RE: als 11 To : "Michele Lee" Hi Michele, How's life? Busy? I actually just had a quick science related question. Do you know of any tissue banks with ALS spinal cord/DRG tissue, preferably in the Bay area? Please drop me a line if you know of any. Thanks a lot! Karen (4) ===== Growth factors ========== Date : Wed, 24 Feb 1993 19:09:20 +0100 Sender : "Neuroscience Information Forum" From : Paul.Herrling@PKFLTG.PHARMA.SANDOZ.CH Subject: ALS To : bro@HUEY.met.FSU.edu Dear ALS group: I just found a note indicating that CEPHALON has recently started a clinical phase II study with Myotrophin (insulin-like growth factor-1). This is the second neuronal growth factor to be tested, the other one being CNTF by Regeneron and/or Synergen. Means we will soon know if growth factors work. Source:SCRIP No 1794 February 12th 1993, p. 25. Kind regards Paul Herrling (5) ===== Biotech stock report - Synergen (re CNTF) ========== ----- From the Washington Post Dow Rises 20.81 but Biotechnology Stocks Plunge NEW YORK, Feb. 22 - Blue-chip stocks ended higher today, but the Nasdaq market was hit by a sharp sell-off in biotechnology stocks. The sell-off in biotechnology shares was triggered by Synergen, which released disappointing test results for its flagship drug Antril. Synergen crumbled 28 5/8 to 13 1/2 on volume of more than 20 million shares, and shares in other biotech companies fell in Synergen's wake. The Nasdaq index slumped 11.19 points to 652.42 under the weight of the biotech sell-off. Among biotechs, Amgen lost 3 1/2 to 41 1/2, Chiron fell 5 1/8 to 45 5/8, Biogen lost 1 3/8 to 26 7/8, Centocor sank 1/2 to 6 1/2, Immunomedics fell 1 5/8 to 7 1/8 and Genentech was off 2 3/8 to 32 3/8. A sell-off among drug stocks continued, also amid government reform concerns and congressional attacks on drug prices. U.S. Surgical was down 4 3/8 at 57 1/8, Medtronic was off 6 1/2 at 70 1/2, Mylan Labs fell 4 7/8 to 25 1/2, Johnson & Johnson lost 1 3/4 to 38 7/8 and Bristol-Myers eased 3/4 to 53 7/8. (6) ===== Searching (continued) ... ========== * DISSERTATION ABSTRACTS * Contains references to U.S. and Canadian Ph.D. dissertations since 1861, and Masters theses since 1962. Includes abstracts of dissertations since 1980. ENTER SUBJECT WORDS -> amyotrophic lateral sclerosis System is now searching Dissertation Abstracts Online database, copyrighted 1993 by University Microfilms International, Ann Arbor, MI and available through BRS Information Technologies. There are 24 item(s) which satisfy your search phrase. TI SPECIFIC ASPECTS OF NEURODEGENERATIVE DISEASE. TI RNA STUDIES IN DEVELOPMENT AND NEURONAL DISEASE (ARTEMIA, AMYOTROPHIC LATERAL SCLEROSIS). TI NON-NMDA RECEPTOR-MEDIATED NEUROTOXICITY IN CORTICAL NEURONAL CULTURES. TI ANATOMY, PHYSIOLOGY, AND PATHOPHYSIOLOGY OF N-ACETYLASPARTYLGLUTAMATE (ACETYLASPARTYLGLUTAMATE, GLUTAMATERGIC PATHWAYS). TI INVOLVEMENT OF THE NERVOUS SYSTEM IN THE IMMUNOBIOLOGY OF MYASTHENIA GRAVIS. TI SPINAL NEURON ABNORMALITIES IN THE MOTOR NEURON DEGENERATION (MND) MOUSE MUTANT. TI THE FORMANT STRUCTURES OF VOWELS AND DIPHTHONGS ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS. TI A TERM BY ANY OTHER NAME: BIZARRENESS, ACCEPTABILITY, NATURALNESS AND NORMALCY JUDGMENTS OF SPEAKERS WITH AMYOTROPHIC LATERAL SCLEROSIS. TI STUDY OF THE INTERRELATIONSHIP BETWEEN DNA SYNTHESIS/CELL REPLICATION AND DNA PROCESSING IN CULTURED HUMAN CELLS. TI TOXICITY OF HEAVY METALS: I. CORRELATION OF METAL TOXICITY WITH IN VITRO CALMODULIN INHIBITION. II. INTERACTIONS OF INORGANIC MERCURY WITH RED BLOOD CELLS: CONTROL VS. AMYOTROPHIC LATERAL SCLEROSIS. TI OROFACIAL MUSCLE WEAKNESS AND MOTOR CONTROL FOR SPEECH IN AMYOTROPHIC LATERAL SCLEROSIS. TI CYCLOPROPANE-CONTAINING AMINO ACIDS USEFUL IN THE SYNTHESIS OF THYROTROPIN RELEASING HORMONE ANALOGUES. TI NA STUDIES OF TRACE-ELEMENT IMBALANCES ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS. TI FACTORS AFFECTING SURVIVAL OF DEVELOPING MOTONEURONS. TI ADVANCES IN FAST ATOM BOMBARDMENT MASS-SPECTROMETRY (GLYCOSPHINGOLIPIDS, NUCLEOTIDES, MARKERS, NEGATIVE ION). TI AN ANALYSIS OF TONGUE STRENGTH AND SWALLOWING EFFICIENCY IN AMYOTROPHIC LATERAL SCLEROSIS. TI DISTRIBUTION OF MAJOR RNA SPECIES IN VENTRAL GRAY OF HUMAN SPINAL CORDS FROM CONTROL AND AMYOTROPHIC LATERAL SCLEROSIS SUBJECTS. TI AUTORADIOGRAPHIC LOCALIZATION OF THYROTROPIN RELEASING HORMONE (TRH) RECEPTORS IN THE CENTRAL NERVOUS SYSTEM. TI APPLICATION OF PATTERN RECOGNITION TECHNIQUES TO IDENTIFY ABNORMAL MACRO EMG MOTOR UNIT POTENTIALS. TI A CASE-CONTROL STUDY OF AMYOTROPHIC LATERAL SCLEROSIS. TI HUMAN NATURAL KILLER CELL ACTIVITY: GENETICS AND ASSOCIATION WITH NEUROLOGIC DISEASE. TI ANALYSIS OF RNA AND VOLUME FROM INDIVIDUAL NEURONS IN AMYOTROPHIC LATERAL SCLEROSIS WITH HISTOLOGIC STUDY. TI INCREASED FERTILITY AMONG AMYOTROPHIC LATERAL SCLEROSIS AND PARKINSONISM-DEMENTIA COMPLEX CASES ON THE ISLAND OF GUAM. TI THE SYNDROME OF AMYOTROPHIC LATERAL SCLEROSIS. == end of als 26 == NFPPPPP . EOT geomag++>